What's in Eye Centers of Southeast Texas's pipeline?

Eye Centers of Southeast Texas has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Eye Centers of Southeast Texas's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eye-centers-of-southeast-texas.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Eye Centers of Southeast Texas — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eye Centers of Southeast Texas pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rocklatan 0.02%-0.005% Ophthalmic Solution	Rocklatan 0.02%-0.005% Ophthalmic Solution	marketed	Prostaglandin analog / Rho kinase inhibitor combination	Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK)	Ophthalmology

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Eye Centers of Southeast Texas:

Cite this brief

Drug Landscape (2026). Eye Centers of Southeast Texas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eye-centers-of-southeast-texas. Accessed 2026-05-17.